A therapeutic treatment demonstrating clinically verified biological age reversal in humans receives FDA appro

Question

Six frontier AI models put this at 9% by 31 Oct 2036. Full reasoning from every model.

WillHappen.ai · Accepted Answer

9% — the median of 6 frontier models, resolving by 2036-10-31.

Answer

Gemini (Google): 8% — The FDA lacks a regulatory framework recognizing biological age reduction as a primary endpoint, requiring proxy disease approvals instead. FDA requires validated clinical outcomes rather than surrogate epigenetic clocks, which take 10+ years to establish in Phase 3 trials. Current candidates like senolytics or metformin target individual age-related diseases rather than receiving a broad age-reversal label. An accelerated approval based purely on biological clocks would require formal FDA guidance changes that typically take over five years to enact.

Answer

Claude (Anthropic): 9% — FDA has no aging-as-disease indication pathway, so approval hinges on a regulatory framework shift that hasn't started. FDA currently doesn't recognize 'biological aging' as an indication; TAME trial and similar efforts have pushed for this for years without success. Even promising senolytics, partial reprogramming, and rapamycin analogs are far from Phase 3 completion with aging-specific biomarker endpoints by mid-2030s. A surprise change would require FDA guidance redefining aging biomarkers as approvable endpoints, which no major regulatory signal currently suggests is imminent.

Answer

GPT (OpenAI): 18% — It turns on FDA accepting a validated aging endpoint and a pivotal trial showing durable benefit, not just biomarker movement. FDA currently approves indications for diseases, and no therapy has an aging-reversal indication or validated surrogate endpoint. A sponsor must first win agreement on endpoints, then complete large controlled trials and review by October 2036. Calorie-restriction mimetics, senolytics and partial reprogramming raise the chance, but safety failures in systemic interventions are a major drag.

Answer

Grok (xAI): 11% — FDA must accept aging biomarkers as endpoints and approve a therapy labeled for reversal. FDA still treats aging as a process not a disease; TAME and similar efforts have not produced an approved reversal indication. No sponsor has a late-stage program with epigenetic or cellular-age primary endpoints that could finish and file by 2034. Novel first-in-class indications historically take >10 years from concept; this case sits well below that base rate unless a landmark trial reports by 2029.

Answer

DeepSeek (DeepSeek): 7% — No FDA pathway exists for 'biological age' as an indication, so approval requires the agency to first accept aging biomarkers as a disease surrogate. The FDA has never approved a drug for an aging indication; metformin and rapamycin trials target specific diseases, not aging itself, and TAME has stalled since 2015. Sponsors would need validated composite biomarkers (epigenetic clocks, p16, etc.) accepted as endpoints, which the FDA has not endorsed for any single therapy as of 2026. The 9-year window is short for a paradigm shift: even the most advanced epigenetic reprogramming (Altos, NewLimit) is preclinical or early Phase 1, with no pivotal trial…

Answer

Qwen (Alibaba): 4% — FDA has never recognized aging reversal as a valid indication; the regulatory pathway itself doesn't yet exist. FDA requires a defined disease for approval; 'biological aging' lacks ICD coding and no guidance document covers it as an endpoint, making NDA submission structurally… No candidate is in Phase 3 with an aging-reversal indication as of late 2026; even TAME (metformin) stalled at the design stage, so a 9-year window can't clear Phase 1–3… A shift would require FDA to issue new guidance accepting epigenetic or biomarker-based age reversal as a primary endpoint—possible but unprecedented within this…

A therapeutic treatment demonstrating clinically verified biological age reversal in humans receives FDA approval before 2035.

What each one said

A therapeutic treatment demonstrating clinically verified biological age reversal in humans receives FDA approval before 2035.

A longevity or anti-aging drug for domestic dogs receives full regulatory approval before 2028.

The FDA approves AbbVie's Biologics License Application for etentamig.

A clinical trial begins testing a vascularized, 3D-bioprinted human organ in patients before 2032.

A fully lab-grown solid human organ is successfully transplanted into a patient before 2035.